.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,545,040

« Back to Dashboard
Patent 6,545,040 protects BYSTOLIC and is included in one NDA. There has been one Paragraph IV challenge on Bystolic.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 6,545,040

Title: Method of lowering the blood pressure
Abstract:A method of potentiating the effects of blood pressure reducing agents in warm-blooded animals, said method comprising administering to said warm-blooded animals of an effective amount of a blood pressure reducing agent and a 2,2'-iminobisethanol derivative.
Inventor(s): Xhonneux; Raymond Mathieu (Vlimmeren, BE), Van Lommen; Guy Rosalia Eugene (Berlaar, BE)
Assignee: Janssen Pharmaceutica N.V. (BE)
Application Number:07/825,488
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Forest Labs
BYSTOLIC
nebivolol hydrochloride
TABLET;ORAL021742-002Dec 17, 2007RXNo6,545,040► subscribeY TREATMENT OF HYPERTENSION
Forest Labs
BYSTOLIC
nebivolol hydrochloride
TABLET;ORAL021742-003Dec 17, 2007RXNo6,545,040► subscribeY TREATMENT OF HYPERTENSION
Forest Labs
BYSTOLIC
nebivolol hydrochloride
TABLET;ORAL021742-004Dec 17, 2007RXNo6,545,040► subscribeY TREATMENT OF HYPERTENSION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,545,040

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria82498► subscribe
Australia3074289► subscribe
Australia621591► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc